Reappearance of fungal infection and its effective treatment with oral antifungal drugs - a clinical trial.

Recurrence of dermatophytosis and therapeutic efficacy of systemic antifungals in adults â?? A randomized, open-label controlled trial in a tertiary institution.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/09/009851

Enrollment

123

Registered

2017-09-20

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Dermatophytosis Health Condition 2: B359- Dermatophytosis, unspecified

Interventions

Intervention1: Terbinafine: Cap Itraconazole 200 mg ODPC + Tab Terbinafine 250 mg ODPC for 4 weeks Intervention2: Itraconazole: Cap Itraconazole- 200mg BDPC for 2 weeks and 100 mg BDPC for next 2 week

Eligibility

Inclusion criteria

Inclusion criteria: (1) Adult patients (15-60 years) with recurrent tinea corporis, cruris or faciei or combinations of these attending our Dermatology OPD, will be the candidates of this study. Most of them present with an extensive form. (2) They have a history of Cap Itraconazole intake (100mg twice daily for at least one month) without interruption and re-occurrence of similar form of tinea after stopping Itraconazole within a short period (one week to six weeks). (3) They must have normal blood count, liver and renal function tests. (4) Positive KOH smear on skin scraping. (5) Regular follow up is possible and complied with to note the improvement and/or any other complications.

Exclusion criteria

Exclusion criteria: (1)Patients with Diabetes Mellitus or other immunocompromised disorders. (2)Patients with H/O steroid or immunosuppressant medicines intake. (3) Pregnant or lactating mother. (4) Other family members will have chronic tinea infections. (5) Patients with other form of tinea infection like tinea pedis, tinea manuum, tinea unguium etc.

Design outcomes

Primary

Measure	Time frame
Clinically free from signs and symptoms of superficial fungal infection and mycologically devoid of any fungal species on fungal culture.Timepoint: At the end of 1st, 2nd and 3rd month for each patient	—

Secondary

Measure	Time frame
Clinically free but culture positivityTimepoint: End of 1st, 2nd and 3rd months.	—

Countries

India

Contacts

Public ContactChinmay Kar

Malda Medical College

karbasabi@gmail.com9434212062

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026